Levetiracetam Injection
Product Images NDC 72572-360

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72572-360). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civica, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural Formula (Levetiracetam Injection Civica 1)

Structural Formula (Levetiracetam Injection Civica 1)
Chemical structure of Levetiracetam, showing its molecular composition with carbon, hydrogen, nitrogen, and oxygen atoms arranged in a specific configuration.*
FDA Label Image

Layout 1 (Levetiracetam Injection Civica 10)

Layout 1 (Levetiracetam Injection Civica 10)
The image shows a label with a QR code alongside printed text containing a GTIN barcode number, a serial number (SN), an expiration date (EXP) placeholder, and a lot number (LOT). The label is designed for track-and-trace purposes but does not display the product name or dosage form explicitly.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Injection Civica 2)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Injection Civica 2)
A bar chart depicting the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows the percentage of patients from 0% to 45%. The placebo group has approximately 7.4%, Levetiracetam 1000 mg/day about 37.1%, and Levetiracetam 3000 mg/day about 39.6%.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Injection Civica 3)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Injection Civica 3)
Bar graph showing the percentage of patients for placebo and two dosage groups of levetiracetam (1000 mg/day and 2000 mg/day). The y-axis represents the percentage of patients, with levetiracetam 2000 mg/day group showing the highest percentage at 35.2%, levetiracetam 1000 mg/day at 20.8%, and placebo at 6.3%.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Injection Civica 4)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Injection Civica 4)
A bar chart comparing the percentage of patients between a placebo group (N=104) and a Levetiracetam 3000 mg/day group (N=180). The vertical axis shows patient percentages, with the placebo group around 14.4% and the Levetiracetam group around 39.4%. An asterisk marks the Levetiracetam bar, indicating statistical significance.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Injection Civica 5)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Injection Civica 5)
A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients, with the Levetiracetam group showing a higher percentage value (44.6%) compared to the Placebo group (19.6%).*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Injection Civica 6)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Injection Civica 6)
A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The vertical axis shows percent of patients from 0% to 45%. The Levetiracetam group has a higher percentage at 43.1%, while the Placebo group is at 19.6%.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Injection Civica 7)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Injection Civica 7)
A bar chart depicting percentages of patients, with two vertical bars labeled 45.2% and 72.2%. The y-axis shows percentage values from 0% to 100%. The chart likely compares patient response rates between two groups.*
FDA Label Image

Plb568 (Levetiracetam Injection Civica 8)

Plb568 (Levetiracetam Injection Civica 8)
Levetiracetam Injection 500 mg per 5 mL (100 mg/mL) single-dose vial label. The label specifies it is for intravenous use only and must be diluted prior to administration. The product is distributed by Civica, Inc. and manufactured by Hikma Farmacêutica (Portugal), S.A. Storage instructions include keeping it at 25°C with allowed excursions. The label includes lot number and expiration date fields along with a barcode.*
FDA Label Image

Plb569 (Levetiracetam Injection Civica 9)

Plb569 (Levetiracetam Injection Civica 9)
Label for Levetiracetam Injection 500 mg per 5 mL (100 mg/mL) intravenous injection by Civica, Inc. The label states that each 5 mL vial contains 500 mg levetiracetam and includes storage, dilution, and usage instructions. The package contains 25 single-dose 5 mL vials. Manufactured by Hikma Farmacéutica (Portugal).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.